19 Aug Trogenix
Ken Macnamara, Ph.D., CEO
Oct. 7 | 9:45am | FLW Ballroom G
Edinburgh, UK
(Private)
Trogenix is a clinical stage cancer gene therapy company with potential for curative responses in solid tumours leveraging our proprietary Odysseus platform to design gene switches that precisely deliver payloads only in target cancer cells. The approach redefines the therapeutic paradigm; strong expression of combination payloads maximizes efficacy, while exquisite selectivity ensures safety. The lead program is entering the clinic H2 2025 for glioblastoma (GBM). Follow-on programs for Hepatocellular Carcinoma (HCC) and Colorectal Liver Mets (CRLM) plus earlier programs in Lung Cancer. The Trogenix Odysseus platform uses a bioinformatics and AI-driven design to create Synthetic Super Enhancers (SSEs), building on the world-leading research of Prof. Steve Pollard’s lab. SSEs are functionally screened in patient-derived primary cells, capturing the heterogeneity of patient tumours. Through this approach, Trogenix has uncovered the Master Transcriptional Network that defines the cellular identity of solid tumours.
